Cancer Therapeutics-Related Cardiac Dysfunction　― Insights From Bench and Bedside of Onco-Cardiology ―

DOI Web Site Web Site PubMed 6 Citations 54 References Open Access
  • Kadowaki Hiroshi
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
  • Akazawa Hiroshi
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
  • Ishida Junichi
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo
  • Komuro Issei
    Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo

Search this article

Abstract

<p>Improvements in the long-term survival of cancer patients have led to growing awareness of the clinical importance of cancer therapeutics-related cardiac dysfunction (CTRCD), which can have a considerable effect on the prognosis and quality of life of cancer patients and survivors. Under such circumstances, onco-cardiology/cardio-oncology has emerged as a new discipline, with the aim of best managing cardiovascular complications, including CTRCD. Despite the recent accumulation of epidemiological and clinical information regarding CTRCD, the molecular mechanisms underlying the pathogenesis of CTRCD by individual drugs remain to be determined. To achieve the goal of preventing cardiovascular complications in cancer patients and survivors, it is important to elucidate the pathogenic mechanisms and to establish diagnostic strategies with risk prediction and mechanism- and evidence-based therapies against CTRCD.</p>

Journal

  • Circulation Journal

    Circulation Journal 84 (9), 1446-1453, 2020-08-25

    The Japanese Circulation Society

Citations (6)*help

See more

References(54)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top